Literature DB >> 26969309

Genetic counseling and cascade genetic testing in Lynch syndrome.

Heather Hampel1.   

Abstract

Lynch syndrome is the most common cause of inherited colorectal and endometrial cancers. Individuals with Lynch syndrome have a 10-80 % lifetime risk for colorectal cancer and a 15-60 % lifetime risk for endometrial cancer. Both cancers are preventable through chemoprevention, intensive cancer surveillance, and risk-reducing surgery options. Efforts to identify as many individuals with Lynch syndrome as possible will prevent cancers and save lives. This includes the traditional cancer genetic counseling model whereby individuals with and without cancer are evaluated for a possible Lynch syndrome diagnosis based on their personal and family history of colon polyps and cancers. It also includes universal tumor screening for Lynch syndrome whereby all individuals with colorectal or endometrial cancer are screened for tumor features of Lynch syndrome at the time of diagnosis. Those with tumors suspicious for Lynch syndrome are referred for cancer genetic counseling regardless of their family history of cancer. This two approaches must be maximized to attain high patient reach. Finally, and perhaps most importantly, cascade testing among the at-risk relatives of those diagnosed with Lynch syndrome is critically important to maximize the diagnosis of individuals with Lynch syndrome. In fact, the cost-effectiveness of universal tumor screening for Lynch syndrome relies entirely on counseling and testing as many at-risk individuals as possible since young unaffected individuals stand to benefit the most from an early diagnosis of Lynch syndrome. This approach must be optimized to achieve high family reach. It will take a concerted effort from patients, clinicians and public health officials to improve current approaches to the diagnosis of Lynch syndrome and the prevention and treatment of Lynch syndrome-associated cancer but these lessons can be applied to other conditions as the ultimate example of personalized medicine.

Entities:  

Keywords:  Cascade testing; Genetic counseling; Genetic testing; Lynch syndrome

Mesh:

Year:  2016        PMID: 26969309     DOI: 10.1007/s10689-016-9893-5

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  39 in total

1.  Validation and extension of the PREMM1,2 model in a population-based cohort of colorectal cancer patients.

Authors:  Francesc Balaguer; Judith Balmaña; Sergi Castellví-Bel; Ewout W Steyerberg; Montserrat Andreu; Xavier Llor; Rodrigo Jover; Sapna Syngal; Antoni Castells
Journal:  Gastroenterology       Date:  2007-10-26       Impact factor: 22.682

2.  Sharing genetic test results in Lynch syndrome: communication with close and distant relatives.

Authors:  Elena M Stoffel; Beth Ford; Rowena C Mercado; Darashana Punglia; Wendy Kohlmann; Peggy Conrad; Amie Blanco; Kristen M Shannon; Mark Powell; Stephen B Gruber; Jonathan Terdiman; Daniel C Chung; Sapna Syngal
Journal:  Clin Gastroenterol Hepatol       Date:  2008-02-07       Impact factor: 11.382

Review 3.  ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.

Authors:  Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt
Journal:  Am J Gastroenterol       Date:  2015-02-03       Impact factor: 10.864

4.  Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.

Authors:  Heather Hampel; Wendy Frankel; Jenny Panescu; Janet Lockman; Kaisa Sotamaa; Daniel Fix; Ilene Comeras; Jennifer La Jeunesse; Hidewaki Nakagawa; Judith A Westman; Thomas W Prior; Mark Clendenning; Pamela Penzone; Janet Lombardi; Patti Dunn; David E Cohn; Larry Copeland; Lynne Eaton; Jeffrey Fowler; George Lewandowski; Luis Vaccarello; Jeffrey Bell; Gary Reid; Albert de la Chapelle
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

5.  One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome.

Authors:  Hans F A Vasen; Mohamed Abdirahman; Richard Brohet; Alexandra M J Langers; Jan H Kleibeuker; Mariette van Kouwen; Jan Jacob Koornstra; Henk Boot; Annemieke Cats; Evelien Dekker; Silvia Sanduleanu; Jan-Werner Poley; James C H Hardwick; Wouter H de Vos Tot Nederveen Cappel; Andrea E van der Meulen-de Jong; T Gie Tan; Maarten A J M Jacobs; Faig Lall A Mohamed; Sijbrand Y de Boer; Paul C van de Meeberg; Marie-Louise Verhulst; Jan M Salemans; Nico van Bentem; B Dik Westerveld; Juda Vecht; Fokko M Nagengast
Journal:  Gastroenterology       Date:  2010-03-02       Impact factor: 22.682

6.  Prediction of MLH1 and MSH2 mutations in Lynch syndrome.

Authors:  Judith Balmaña; David H Stockwell; Ewout W Steyerberg; Elena M Stoffel; Amie M Deffenbaugh; Julia E Reid; Brian Ward; Thomas Scholl; Brant Hendrickson; John Tazelaar; Lynn Anne Burbidge; Sapna Syngal
Journal:  JAMA       Date:  2006-09-27       Impact factor: 56.272

7.  Development and validation of a colon cancer risk assessment tool for patients undergoing colonoscopy.

Authors:  Fay Kastrinos; John I Allen; David H Stockwell; Elena M Stoffel; Earl F Cook; Muthoka L Mutinga; Judith Balmaña; Sapna Syngal
Journal:  Am J Gastroenterol       Date:  2009-04-28       Impact factor: 10.864

Review 8.  Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis.

Authors:  Gaëtan Des Guetz; Olivier Schischmanoff; Patrick Nicolas; Gérard-Yves Perret; Jean-François Morere; Bernard Uzzan
Journal:  Eur J Cancer       Date:  2009-05-06       Impact factor: 9.162

9.  The cost-effectiveness of routine testing for Lynch syndrome in newly diagnosed patients with colorectal cancer in the United States: corrected estimates.

Authors:  Scott D Grosse; Glenn E Palomaki; Mercy Mvundura; Heather Hampel
Journal:  Genet Med       Date:  2015-06       Impact factor: 8.822

10.  ACOG Practice Bulletin No. 147: Lynch syndrome.

Authors: 
Journal:  Obstet Gynecol       Date:  2014-11       Impact factor: 7.661

View more
  37 in total

1.  Utilization of Genetic Testing for RET Mutations in Patients with Medullary Thyroid Carcinoma: a Single-Center Experience.

Authors:  Emily Parkhurst; Elise Calonico; Sridevi Abboy
Journal:  J Genet Couns       Date:  2018-06-27       Impact factor: 2.537

2.  Worldwide Practice Patterns in Lynch Syndrome Diagnosis and Management, Based on Data From the International Mismatch Repair Consortium.

Authors:  Jennifer Y Pan; Robert W Haile; Allyson Templeton; Finlay Macrae; FeiFei Qin; Vandana Sundaram; Uri Ladabaum
Journal:  Clin Gastroenterol Hepatol       Date:  2018-04-24       Impact factor: 11.382

3.  Unsolicited information letters to increase awareness of Lynch syndrome and familial colorectal cancer: reactions and attitudes.

Authors:  Helle Vendel Petersen; Birgitte Lidegaard Frederiksen; Charlotte Kvist Lautrup; Lars Joachim Lindberg; Steen Ladelund; Mef Nilbert
Journal:  Fam Cancer       Date:  2019-01       Impact factor: 2.375

4.  The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.

Authors:  Fred H Menko; Jacqueline A Ter Stege; Lizet E van der Kolk; Kiki N Jeanson; Winnie Schats; Daoud Ait Moha; Eveline M A Bleiker
Journal:  Fam Cancer       Date:  2019-01       Impact factor: 2.375

5.  Patterns of family communication and preferred resources for sharing information among families with a Lynch syndrome diagnosis.

Authors:  Jenna Petersen; Cathryn Koptiuch; Yelena P Wu; Ryan Mooney; Ashley Elrick; Kathryn Szczotka; Megan Keener; Lisa Pappas; Priyanka Kanth; Andrew Soisson; Wendy Kohlmann; Kimberly A Kaphingst
Journal:  Patient Educ Couns       Date:  2018-07-26

6.  Genetic testing in families with hereditary colorectal cancer in British Columbia and Yukon: a retrospective cross-sectional analysis.

Authors:  Vivienne K Beard; Angela C Bedard; Jennifer Nuk; Petra W C Lee; Quan Hong; James E J Bedard; Sophie Sun; Kasmintan A Schrader
Journal:  CMAJ Open       Date:  2020-10-19

7.  How Primary Care Providers Talk to Patients about Genome Sequencing Results: Risk, Rationale, and Recommendation.

Authors:  Jason L Vassy; J Kelly Davis; Christine Kirby; Ian J Richardson; Robert C Green; Amy L McGuire; Peter A Ubel
Journal:  J Gen Intern Med       Date:  2018-01-26       Impact factor: 5.128

8.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer.

Authors:  Naohiro Tomita; Hideyuki Ishida; Kohji Tanakaya; Tatsuro Yamaguchi; Kensuke Kumamoto; Toshiaki Tanaka; Takao Hinoi; Yasuyuki Miyakura; Hirotoshi Hasegawa; Tetsuji Takayama; Hideki Ishikawa; Takeshi Nakajima; Akiko Chino; Hideki Shimodaira; Akira Hirasawa; Yoshiko Nakayama; Shigeki Sekine; Kazuo Tamura; Kiwamu Akagi; Yuko Kawasaki; Hirotoshi Kobayashi; Masami Arai; Michio Itabashi; Yojiro Hashiguchi; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2021-06-29       Impact factor: 3.402

9.  First description of mutational analysis of MLH1, MSH2 and MSH6 in Algerian families with suspected Lynch syndrome.

Authors:  H Ziada-Bouchaar; K Sifi; T Filali; T Hammada; D Satta; N Abadi
Journal:  Fam Cancer       Date:  2017-01       Impact factor: 2.375

Review 10.  Incorporating Colorectal Cancer Genetic Risk Assessment into Gastroenterology Practice.

Authors:  Benjamin Stern; Thomas McGarrity; Maria Baker
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.